Methotrexate for Injection USP

Published Online: Thursday, December 1, 2005

Bedford Laboratories (Bedford, Ohio), a division of Ben Venue Laboratories Inc, recently added Methotrexate for Injection USP, 1 g, to its line of oncology products. Methotrexate for Injection USP is indicated for the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis. The product is supplied in 4 singledose, preservative-free liquid presentations, containing 25 mg/mL of methotrexate sodium?50 mg in 2 mL, 100 mg in 4 mL, 200 mg in 8 mL, 250 mg in 10 mL?and in a 1- g single-dose, preservative-free lyophilized powder. For more information, visit www.bedfordlabs.com, or call 800-521-5169.



Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues
$auto_registration$
VSEO N/A